Results 91 to 100 of about 471 (127)

Comparison of in vitro activity of cefepime-enmetazobactam and other carbapenem-sparing agents for gram-negative uropathogens

open access: yesIP International Journal of Medical Microbiology and Tropical Diseases
Kalaivani Ramakrishnan   +4 more
openaire   +1 more source

In Vitro efficacy of Cefepime/Enmetazobactam against AmpC ßlactamase-producing Enterobacterales

open access: yes
Marlat, Clément   +6 more
openaire   +1 more source

Impact of inoculum effect on in vitro activity of Cefepime-Enmetazobactam against ESBLproducing Escherichia coli

open access: yes
Giry, Marion   +10 more
openaire   +1 more source

Activity of Cefepime-Enmetazobactam against ESBL and AmpC-coproducing Enterobacterales in Hollow-Fiber Infection Model

open access: yes
Bossé, Clément   +8 more
openaire   +1 more source

Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2020
Cefepime-enmetazobactam is a novel β-lactam–β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae . This agent is being developed for a range of serious hospital infections.
William Hope, Jesús Reiné, Elena Mitsi
exaly   +5 more sources

Cefepime/Enmetazobactam: A Microbiological, Pharmacokinetic, Pharmacodynamic, and Clinical Evaluation

open access: yesExpert Opinion on Drug Metabolism and Toxicology
Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor (BL-BLI) combination with broad Gram-positive and -negative activity. Cefepime is relatively resistant to hydrolysis by AmpC, and enmetazobactam inhibits all Ambler Class A extended spectrum β-lactamases (ESBLs). Hence, the combination is resistant to hydrolysis by many ESBLs.
William Hope   +2 more
exaly   +4 more sources

Home - About - Disclaimer - Privacy